Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN51,9752,01-0,57
Msft-6,05
Nokia4,18454,3595-1,73
IBM0,89
Mercedes-Benz Group AG55,8755,89-1,24
PFE-0,77
01.11.2024 0:24:55
Indexy online
AD Index online
select
AD Index online
 

  • 31.10.2024 17:35:58
Astra Zeneca (AZN.DE, Xetra)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
131,30 -2,23 -3,00 1 505 465
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.11.2024
Popis společnosti
Obecné informace
Název společnostiAstraZeneca plc
TickerAZN
Kmenové akcie:Ordinary Shares
RICAZN.L
ISINGB0009895292
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 89 900
Akcie v oběhu k 30.09.20241 550 294 658
MěnaUSD
Kontaktní informace
Ulice1 Francis Crick Avenue
MěstoCAMBRIDGE
PSČCB2 0AA
ZeměUnited Kingdom
Kontatní osobaAndy Barnett
Funkce kontaktní osobyHead of Investor Relations
Telefon442 073 045 000
Fax442076048151

Business Summary: AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Financial Summary: BRIEF: For the six months ended 30 June 2024, AstraZeneca plc revenues increased 15% to $25.62B. Net income increased 13% to $4.11B. Revenues reflect Koselugo segment increase of 44% to $114M, Tezspire segment increase of 90% to $57M. Net income was partially offset by Research and development expense - Balan increase of 14% to $5.57B (expense), Selling, General & Administrative Expens increase of 10% to $7.15B (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSOffices of Other Holding Companies
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Offices of Other Holding Companies
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Offices of Other Holding Companies
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 01.11.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorPascal Soriot6401.10.201201.10.2012
Chief Financial Officer, Executive DirectorAradhana Sarin-01.08.202101.08.2021
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZenecaMarc Dunoyer7001.08.202101.01.2013
Chief Human Resource Officer, Chief Compliance Officer, General CounselJeffrey Pott-01.01.2009
Executive Vice President - BioPharmaceuticals R&DSharon Barr-
Executive Vice President - Global Operations, Information Technology and Chief Sustainability OfficerPam Cheng-
Executive Vice President - BioPharmaceuticals Business UnitRuud Dobber59
Executive Vice President - Oncology Business UnitDavid Fredrickson-
Executive Vice President - Oncology and Research and DevelopmentSusan Galbraith-
Executive Vice President - Vaccines and Immune TherapiesIskra Reic-